Anebulo Pharmaceuticals Files 8-K: Material Agreement, Equity Sales
Ticker: ANEB · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1815974
| Field | Detail |
|---|---|
| Company | Anebulo Pharmaceuticals, Inc. (ANEB) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $0, $15 m, $3 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, change-of-control
TL;DR
Anebulo Pharma signed a big deal, sold some stock, and might have a new boss. Details to come.
AI Summary
On December 22, 2024, Anebulo Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported unregistered sales of equity securities and changes in control. Specific details regarding the agreement, sales, and control changes were not provided in this initial filing.
Why It Matters
This filing indicates significant corporate actions, including a material definitive agreement and potential changes in control, which could impact the company's future operations and stock value.
Risk Assessment
Risk Level: medium — The filing mentions a material definitive agreement, unregistered sales of equity, and changes in control, all of which can introduce significant uncertainty and risk.
Key Players & Entities
- Anebulo Pharmaceuticals, Inc. (company) — Registrant
- December 22, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Anebulo Pharmaceuticals?
The filing states that Anebulo Pharmaceuticals, Inc. entered into a material definitive agreement on December 22, 2024, but the specific terms and counterparty are not detailed in this report.
What type of unregistered sales of equity securities occurred?
The 8-K filing indicates that Anebulo Pharmaceuticals, Inc. engaged in unregistered sales of equity securities, but the specifics of these sales, such as the amount or terms, are not provided.
What changes in control of the registrant are being reported?
The filing notes changes in control of Anebulo Pharmaceuticals, Inc., but the details regarding the nature of these changes or the parties involved are not disclosed in this document.
What is the principal business address of Anebulo Pharmaceuticals, Inc.?
The principal executive office address for Anebulo Pharmaceuticals, Inc. is 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 22, 2024.
Filing Stats: 1,342 words · 5 min read · ~4 pages · Grade level 13.1 · Accepted 2024-12-23 16:56:37
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ANEB The Nasdaq
- $0 — ). The purchase price of each Share was $0.99, equal to the Nasdaq Minimum Price,
- $15 m — the Private Placement of approximately $15 million, before deducting estimated offer
- $3 m — the maximum loan size to approximately $3 million, which reduces the LSA to just un
Filing Documents
- form8-k.htm (8-K) — 52KB
- ex10-1.htm (EX-10.1) — 233KB
- ex99-1.htm (EX-99.1) — 25KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-051853.txt ( ) — 553KB
- aneb-20241222.xsd (EX-101.SCH) — 3KB
- aneb-20241222_lab.xml (EX-101.LAB) — 33KB
- aneb-20241222_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Form of Securities Purchase Agreement, dated December 23, 2024, by and between the Company and the purchasers listed on the signature page thereto 99.1 Press Release dated December 23, 2024 104 Cover Page of Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANEBULO PHARMACEUTICALS, INC. Date: December 23, 2024 By: /s/ Richard Anthony Cunningham Richard Anthony Cunningham Chief Executive Officer ( Principal Executive Officer )